Results 151 to 160 of about 22,236,668 (323)

Treatment-emergent adverse events.

open access: yes, 2015
Treatment-emergent adverse events affecting ≥15% of subjects treated with BG00010 (any dose) or ≥15% of subjects treated with placebo.i.v., intravenous; N/A, not applicable; s.c., subcutaneous.Treatment-emergent adverse events.
Jitesh Rana (737072)   +6 more
core   +1 more source

Ofatumumab in Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease: A Comparison With Rituximab

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To evaluate the efficacy and safety of ofatumumab in patients with myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD), and compare it with rituximab. Methods We conducted a single–center, observational study including 22 MOGAD patients treated with ofatumumab and 21 treated with rituximab.
Yuxin Fan   +5 more
wiley   +1 more source

Active drug-safety monitoring and management in the treatment of rifampicin-resistant tuberculosis: a nationwide multicenter prospective study

open access: yesJournal of Microbiology, Immunology and Infection
Background: Active tuberculosis drug-safety monitoring and management (aDSM) is recommended in the treatment of rifampicin-resistant tuberculosis. We established comprehensive aDSM and conducted a nationwide multicenter prospective study in Taiwan ...
Chou-Jui Lin   +7 more
doaj   +1 more source

Cutaneous Adverse Events Related To Treatment With Imatinib

open access: yes, 2014
Treatment with Imatinib is generally well-tolerated, and in the majority of patients side effects are only represented by mild to moderate haematological toxicity (Druker 2001).
SAVOIA, Paola, Fava Paolo
core  

White Matter Hyperintensity Burden and Short‐Interval Change Associated With Sleep Apnoea in the UK Biobank

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background and Purpose White matter hyperintensities (WMH) are a core neuroimaging marker of cerebral small vessel disease (CSVD). Sleep apnoea (SA) is a recognized vascular risk factor, but its associations with regional WMH burden, short‐interval WMH change and cognitive performance in population‐based cohorts remain incompletely defined. We
Peng Cheng   +4 more
wiley   +1 more source

Impact of immune‐related adverse events on survival outcomes in extensive‐stage small cell lung cancer patients treated with immune checkpoint inhibitors

open access: yesCancer Medicine
Background Immune checkpoint inhibitors have recently become the standard of care in the first‐line treatment of extensive‐stage small cell lung cancer.
Tadashi Nishimura   +21 more
doaj   +1 more source

Economic burden related to chemotherapy-related adverse events in patients with metastatic breast cancer in an integrated health care system

open access: yes, 2016
Nazia Rashid,1 Han A Koh,2 Hilda C Baca,3 Kathy J Lin,1 Susan E Malecha,4 Anthony Masaquel5 1Drug Information Services, Kaiser Permanente, Downey, 2Southern California Permanente Medical Group, Kaiser Permanente, Bellflower, 3Pharmacy Analytical Services,
Koh HA   +5 more
core  

Drug related adverse events.

open access: yes, 2015
VL–visceral leishmaniasis*two of the renal impairments occurred in patients admitted for severe pneumonia who eventually died while on treatment. But as pentamidine is also known for its renal effect, they were considered as possibly pentamidine related ...
Fabiana Alves (217602)   +15 more
core   +1 more source

Treatment emergent adverse events (AEs).

open access: yes, 2020
Treatment emergent adverse events (AEs).
Andrea Kuemmerle (296573)   +10 more
core   +1 more source

Long‐Term Efficacy of Immunotherapy in Autoimmune Autonomic Ganglionopathy—A 10‐Year Follow Up Study

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Autoimmune autonomic ganglionopathy (AAG) is a rare but potentially treatable cause of severe autonomic failure. Evidence guiding long‐term immunotherapy, treatment sequencing, and residual autonomic impairment is limited. We evaluated long‐term treatment response, residual autonomic dysfunction, and relapse patterns in patients with
Giacomo Chiaro   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy